BRAF V600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: A Meta-Analysis

被引:221
|
作者
Li, Carol [1 ]
Lee, Kathleen C. [1 ]
Schneider, Eric B. [1 ]
Zeiger, Martha A. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Endocrine Surg Sect, Baltimore, MD 21287 USA
来源
基金
美国国家卫生研究院;
关键词
ASPIRATION BIOPSY SPECIMENS; LYMPH-NODE METASTASIS; TALL-CELL VARIANT; BRAF(V600E) MUTATION; HIGH PREVALENCE; GENE MUTATION; HIGH-RISK; CARCINOMA; RECURRENCE; EXPRESSION;
D O I
10.1210/jc.2012-2104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There is conflicting literature regarding the association of the BRAF V600E mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC). Nevertheless, some propose that BRAF status be incorporated into the management of patients with PTC, specifically recommendations regarding lymph node dissection. We therefore performed a meta-analysis to examine the relationship between BRAF and clinicopathological features of PTC. Methods: A literature search was performed within PubMed and EMBASE databases using the following Medical Subject Headings (MeSH) and keywords: "braf," "mutation," "thyroid," "neoplasm(s)," "tumor," "cancer," and "carcinoma." Individual study-specific odds ratios and confidence intervals were calculated, as were Mantel-Haenszel pooled odds ratios for the combined studies. Results: Thirty-two studies including 6372 patients were reviewed. BRAF mutation was associated with lymph node metastases (LNM), advanced stage, extrathyroidal extension, tumor size, male gender, multifocality, absence of capsule, classic PTC, and tall-cell variant PTC. There was no association with age or vascular invasion. Only two studies were prospective; nine included consecutive patients, whereas one included randomly selected patients; and only two included patients who had undergone routine central lymph node dissection and were thus evaluable for the presence of LNM. Conclusion: Meta-analysis found that BRAF mutation is associated with LNM, stage, extrathyroidal extension, tumor size, male gender, multifocality, absence of capsule, classic PTC, and tall-cell variant PTC in PTC. However, almost all studies were retrospective and only two of 32 included patients who had undergone routine central lymph node dissection, emphasizing the need for well-designed studies to appropriately examine this association before making important clinical decisions. (J Clin Endocrinol Metab 97: 4559-4570, 2012)
引用
收藏
页码:4559 / 4570
页数:12
相关论文
共 50 条
  • [41] Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules
    Beisa, Augustas
    Kvietkauskas, Mindaugas
    Beisa, Virgilijus
    Stoskus, Mindaugas
    Ostaneviciute, Elvyra
    Jasiunas, Eugenijus
    Griskevicius, Laimonas
    Seinin, Dmitrij
    Sileikyte, Aukse
    Strupas, Kestutis
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2019, 127 (04) : 247 - 254
  • [42] Diagnostic significance of the BRAF V600E mutation in conventional papillary thyroid carcinomas
    Zhang, Bo
    Xu, Chun-Wei
    Wu, Yong-Fang
    Man, Qiu-Hong
    Song, Ye-Ying
    Wang, Jing-Jing
    Wang, Huai-Tao
    Wang, Hai-Yan
    Li, Xiao-Bing
    Zhang, Hao
    Ye, Ting
    Zhang, Zhe
    Cai, Cong-Li
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (05): : 8296 - 8303
  • [43] Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation
    Lin, Yan
    Wu, Zhao-rong
    Shi, Yao-ping
    Ding, Min
    Tang, Xiao-yin
    He, Yi
    Zhai, Bo
    Li, Ping
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (11): : E1298 - E1305
  • [44] BRAF V600E in Pediatric Papillary Thyroid Carcinomas
    Paulson, V. A.
    Hollowell, M. L.
    Huang, S. A.
    Barletta, J. A.
    LABORATORY INVESTIGATION, 2014, 94 : 157A - 157A
  • [45] Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population
    Brzezianska, Ewa
    Pastuszak-Lewandoska, Dorota
    Wojciechowska, Katarzyna
    Migdalska-Sek, Monika
    Cyniak-Magierska, Anna
    Nawrot, Ewa
    Lewinski, Andrzej
    NEUROENDOCRINOLOGY LETTERS, 2007, 28 (04) : 351 - 359
  • [46] The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer
    Beisa, Augustas
    Beisa, Virgilijus
    Stoskus, Mindaugas
    Ostaneviciute, Elvyra
    Griskevicius, Laimonas
    Strupas, Kestutis
    ENDOKRYNOLOGIA POLSKA, 2016, 67 (01) : 35 - 40
  • [47] Lack of MAPK activation in papillary thyroid carcinoma with BRAF V600E mutation
    Zuo, Hui
    Nakamura, Yasushi
    Yasuoka, Hironao
    Nakamura, Misa
    Mori, Ichiro
    Miyauchi, Akira
    Kakudo, Kennichi
    CANCER RESEARCH, 2006, 66 (08)
  • [48] Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
    Han, Ying
    Hou, Ling
    Zhao, Bowen
    Gao, Li
    Li, Shiyan
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [49] BRAF V600E and lymph node metastases in papillary thyroid cancer
    Chen, Pan
    Pan, Liqin
    Huang, Wensi
    Feng, Huijuan
    Ouyang, Wei
    Wu, Juqing
    Wang, Jing
    Deng, Yuying
    Luo, Jiaxin
    Chen, Yanying
    ENDOCRINE CONNECTIONS, 2020, 9 (10) : 999 - 1008
  • [50] BRAF V600E in Pediatric Papillary Thyroid Carcinomas
    Paulson, V. A.
    Hollowell, M. L.
    Huang, S. A.
    Barletta, J. A.
    MODERN PATHOLOGY, 2014, 27 : 157A - 157A